IP Library Granted Patent US 9,585,925
Granted Patent B1
US 9,585,925 · App. 13/833,837 · Granted Mar 7, 2017

Pet food supplement

Inventor: Jamy A. Bascharon (Lisle, IL)
Assignee: Vetnique Labs LLC
A61K36/42A61K31/353A61K35/744A61K35/747
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,585,925
App. No.
13/833,837
Granted
Mar 7, 2017
Kind
B1
Abstract

This disclosure relates to methods of treating anal gland disease in subjects. In particular, the disclosure provides supplement compositions useful for treatment of anal gland disease. Such compositions comprise a probiotic, a fiber source, and an anti-inflammatory agent.

Claims (22)

1. A composition comprising (1) a probiotic, a prebiotic, or both, (2) a fiber source, and (3) quercetin, where quercetin is present in the amount of about 3 weight % to about 5 weight %, and where the composition reduces inflammation of anal glands.

2. A composition according to claim 1 further comprising a digestive enzyme.

3. A composition according to claim 2 , wherein the digestive enzyme is bromelain.

4. The composition according to claim 2 , further comprising apple pectin.

5. A composition comprising (1) a probiotic, where the probiotic is present in the amount of about 1×10 3 to about 1×10 10 colony-forming units, (2) a fiber source, and (3) quercetin, where quercetin is present in the amount of about 3 weight % to about 5 weight %.

6. The composition according to claim 5 , further comprising an anti-histamine agent.

7. The composition according to claim 5 , further comprising one or more of vitamins, minerals, or a combination thereof.

8. The composition according to claim 5 , comprising the probiotic that is a strain selected from the group consisting of Bifidobacterium, Lactobacillus, Lactococcus, Saccharomyces, Streptococcus , and a combination thereof.

9. The composition according to claim 8 , wherein the probiotic is Lactobacillus acidophilus.

10. The composition according to claim 5 , wherein the fiber source is selected from the group consisting of barley, flax seed, digestion resistant maltodextrin, beet pulp, guar gum, inulin, cellulose, larch arabinogalactan, methylcellulose, oat bran, oligofructose, pectin, pumpkin powder, pumpkin seed, psyllium , rice bran, wheat bran, wheat dextrin, and a combination thereof.

11. The composition according to claim 5 , further comprising an agent for improvement of flavor.

12. The composition according to claim 5 , which comprises: L. Acidophilus , pumpkin seed, and bromelain.

13. The composition according to claim 12 , further comprising apple pectin.

14. A composition comprising (1) two or more fiber sources, (2) quercetin, where quercetin is present in the amount of about 3 weight % to about 5 weight %, and (3) at least one additional agent selected from the group selected from a probiotic, a prebiotic, an anti-inflammatory agent, and an anti-histamine.

15. The composition according to claim 14 , wherein the fiber source is selected from the group consisting of barley, flax seed, digestion resistant maltodextrin, beet pulp, guar gum, inulin, cellulose, larch arabinogalactan, methylcellulose, oat bran, oligofructose, pectin, pumpkin powder, pumpkin seed, psyllium , rice bran, wheat bran, wheat dextrin, and a combination thereof.

16. The composition according to claim 14 , comprising the probiotic, which is Lactobacillus acidophilus.

17. The composition according to claim 14 , comprising the anti-inflammatory agent that is selected from the group consisting of fish oil, bromelain, Vitamin C, Vitamin E, L-glutathione, selenium, reservatol, papain, flax seed oil, curcumin, ginger, alpha lipoic acid, zinc, and a combination thereof.

18. A method of treatment or prevention of anal gland disease, the method comprising administering to a subject in need of such treatment an effective amount of one or more compositions according to claim 5 .

19. The method according to claim 18 , wherein the subject is a dog or a cat.

20. A method of treatment or prevention of anal gland disease, the method comprising administering to a subject in need of such treatment an effective amount of one or more compositions according to claim 14 .

21. The method according to claim 20 , wherein the subject is a dog or a cat.

22. The composition according to claim 14 , wherein an anti-inflammatory agent is bioflavonoid selected from the group consisting of epicatechin, oligomeric proanthocyanidins, kaempferol, myricetin, fisetin, isorhamnetin, pachypodol, rhamnazin, luteolin, apigenin, tangeritin, hesperetin, naringenin, eriodictyol, homoeriodictyol, taxifolin, and dihydrokaempferol.

Assignments (7)
CHANGE OF ENTITY JURISDICTION FROM ILLINOIS LLC TO A DELAWARE LLC Recorded Jun 1, 2026
From: VETNIQUE LABS LLC
To: VETNIQUE LABS LLC
Reel/Frame 075669/0756 →
RELEASE OF SECURITY INTEREST Recorded May 22, 2026
From: FORTRESS CREDIT CORP.
To: VETNIQUE LABS LLC; WALKIN PETS INC.
Reel/Frame 074739/0388 →
SECURITY INTEREST Recorded May 19, 2026
From: VETNIQUE LABS LLC
To: CRESTLINE DIRECT FINANCE, L.P., AS AGENT
Reel/Frame 074692/0302 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2024
From: LBC CREDIT AGENCY SERVICES, LLC, AS ADMINISTRATIVE AGENT
To: VETNIQUE LABS LLC
Reel/Frame 068141/0776 →
SECURITY INTEREST Recorded Jul 31, 2024
From: VETNIQUE LABS, LLC; WALKIN PETS INC.
To: FORTRESS CREDIT CORP.
Reel/Frame 068142/0900 →
SECURITY INTEREST Recorded Feb 13, 2024
From: VETNIQUE LABS LLC
To: LBC CREDIT AGENCY SERVICES, LLC, AS AGENT
Reel/Frame 066449/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: BASCHARON, JAMY A.
To: VETNIQUE LABS LLC
Reel/Frame 040864/0133 →
Continuity (1)
Provisional Application 61642895 · May 4, 2012